MedPath

Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III

Completed
Conditions
Breast Cancer
Registration Number
NCT02663973
Lead Sponsor
Latin American Cooperative Oncology Group
Brief Summary

The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population

Detailed Description

The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population. Other specific goals are:

* To evaluate the demographic and socio-demographic profile, comorbidities and reproductive risks, anthropometric profile and family history.

* Characterize the breast tumors immunophenotype through anatomopathological data, such as: tumor grade, estrogen receptor, progesterone receptor, HER2, Ki67.

* Describe the screening tests, main symptoms and cancer stage in the moment of the diagnosis.

* Describe the initial cancer treatment and locally advanced such as surgery, radiotherapy, chemotherapy and endocrine therapy.

* Describe palliative treatment for recurrent or metastatic breast cancer: chemotherapy, radiotherapy, biphosphonate, and others.

* Evaluate the clinical outcomes such as: local or diffuse relapse, period of time until progression to metastatic cancer, global lifespan and specific breast cancer lifespan.

* Evaluate clinical complications of the metastatic disease, such as: brain metastasis, spinal cord compression, skeletal related events.

* Analyze the demographical and socio-economical characteristics, clinical-pathological characteristics of the tumor, treatment, clinical outcomes, type of institution (private/public), and other factors that may impact clinical outcome.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
3000
Inclusion Criteria
  • Woman ≥ 18 years old
  • Invasive breast cancer stage I to IV proven by histology or cytology
  • Patients with new pathological diagnosis of invasive primary BC after the site activation date
  • Pathological diagnosis of invasive breast cancer during recruitment (6 months before center activation or until 3000 patients included)
  • New primary cancer on the same breast or contralateral breast.
  • Patient's medical chart is available and adequate for data collection
  • Patient properly signed the informed consent form
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Description of the epidemiology of breast cancer in the Brazilian populationAnnually, during 5 years
Secondary Outcome Measures
NameTimeMethod
Characterization of the immunophenotypic markers of the tumorAnnually, during 5 years

estrogen receptor, progesterone receptor, HER2, Ki67

Initial treatment for breast cancer of Brazilian patientsAnnually, during 5 years
Main symptoms presented by patients with breast cancer in BrazilAnnually, during 5 years
Type of palliative treatment for metastasis or recurrent breast cancer in Brazilian patientsAnnually, during 5 years
Types of clinical complications displayed by breast cancer Brazilian patientsAnnually, during 5 years
Description of the socioeconomical characteristics of the Brazilian population with breast cancerAnnually, during 5 years
Classification of breast cancer stagingAnnually, during 5 years
Description of screening tests of breast cancer patients in BrazilAnnually, during 5 years
Clinical outcome of Brazilian breast cancer patientsAnnually, during 5 years
Characterization of exterior factors that may impact clinical outcome of breast cancer Brazilian patientsAnnually, during 5 years

Trial Locations

Locations (24)

Hospital AC Camargo

🇧🇷

São Paulo, Brazil

Centro de Pesquisas da Serra Gaúcha

🇧🇷

Caxias do Sul, Rio Grande Do Sul, Brazil

Oncoclínica

🇧🇷

Rio de Janeiro, Brazil

Centro Regional Integrado de Oncologia (CRIO)

🇧🇷

Fortaleza, Ceará, Brazil

Instituto Nacional do Câncer

🇧🇷

Rio de Janeiro, Brazil

Centro de Pesquisa Instituto do Câncer Arnaldo Vieira de Carvalho

🇧🇷

São Paulo, Brazil

Hospital São Vicente de Paulo

🇧🇷

Passo Fundo, Rio Grande Do Sul, Brazil

Instituto de Pesquisa Clínicas para Estudos Multicêntricos da UCS

🇧🇷

Caxias do Sul, Rio Grande Do Sul, Brazil

Centro de Pesquisa Clínica da Liga Norte Riograndense Contra o Câncer

🇧🇷

Natal, Rio Grande Do Norte, Brazil

Núcleo de Oncologia da Bahia

🇧🇷

Salvador, Bahia, Brazil

Grupo de Estudos em Pesquisa de Pelotas

🇧🇷

Pelotas, Rio Grande Do Sul, Brazil

CPO - Pucrs

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Hospital Moinhos de Vento

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Hospital da Cidade de Passo Fundo - Clínica CITO

🇧🇷

Passo Fundo, Rio Grande Do Sul, Brazil

Novos Tratamentos em Câncer - Hospital Santa Casa de Porto Alegre

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Clínica AMO

🇧🇷

Salvador, Bahia, Brazil

Hospital Jardim Amália

🇧🇷

Volta Redonda, Rio De Janeiro, Brazil

Centro de Pesquisa Clínica do Hospital Israelita Albert Einstein

🇧🇷

São Paulo, Brazil

Unidade de Pesquisa Clínica/Hospital de Clínicas da UFG

🇧🇷

Goiânia, Goiás, Brazil

Instituto Oncológico de Ribeirão Preto - InORP

🇧🇷

Ribeirão Preto, São Paulo, Brazil

CEPON

🇧🇷

Florianópolis, Santa Catarina, Brazil

Centro de Pesquisa do Setor de Ginecologia e Mama do Hospital Araújo Jorge

🇧🇷

Goiânia, Goiás, Brazil

Unidade de Pesquisa Clínica do Hospital do Câncer de Londrina

🇧🇷

Londrina, Paraná, Brazil

Clínica de Neoplasias Litoral - Centro de Novos Tratamentos Itajaí

🇧🇷

Itajaí, Santa Catarina, Brazil

© Copyright 2025. All Rights Reserved by MedPath